Monoclonal antibody therapy for solid tumors

Cancer Treatment Reviews

Volumn 26, Issue 4, 2000, Pages 269-286

  Green, M C ^a   Murray, J L ^a   Hortobagyi, Gabriel N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Breast cancer; Colon cancer; Growth factor receptors; Lung cancer; Monoclonal antibody therapy; Review

Indexed keywords

MONOCLONAL ANTIBODY; RITUXIMAB; TRASTUZUMAB;

BREAST CANCER; CANCER IMMUNOTHERAPY; COLON CANCER; LUNG CANCER; REVIEW; SOLID TUMOR;

EID: 0034254157     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1053/ctrv.2000.0176     Document Type: Review

References (172)

1. Wright P. W., Hellstrom K. E., Hellstrom E., Bernstein I. D. Serotherapy of malignant disease. Med Clin North Am. 60:1976;607-622.
2. Kohler G., Milstein G. Continuous culture of fused cells secreting antibody of predefined specificity. Nature. 256:1975;495-497.
3. Nadler L. M., Staashenko P., Hardy R. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res. 40:1980;3147-3154.
4. Miller R. A., Maloney D. G., McKillop J., Levy R. In vivo effects of murine hybridoma monoclonal antibody in a patient with T-cell leukemia. Blood. 58:1981;78-86.
5. Sears H. F., Atkinson B., Mattis J. Phase I clinical trial of monoclonal antibody in treatment of gastrointestinal tumors. Lancet. 1:1982;762-765.
6. Roitt I., Male D. Introduction to the immune system. Roitt I., Brostoff J., Male D. Immunology,5th edn. 1998;7 Mosby International Ltd, London.
7. Bast R. C., Mills G. B., Gibson S., Boyer C. M., Holland J. F., Bast R. C., Weichselbaum R. R. Tumor immunology. Cancer Medicine. 1997;Williams and Wilkins, Baltimore. p. 229.
8. Khazaeli M. B., Conry R., Lo Buglio A. Human immune response to monoclonal antibodies. J Immunol. 15:1994;42.
9. Bast R. C., Mills G. B., Gibson S., Boyer C. M., Holland J. F., Bast R. C., Weichselbaum R. R. Tumor immunology. Cancer Medicine. 1997;Williams and Wilkins, Baltimore. p. 231.
10. Trauth B., Klas C., Peters A. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science. 245:1989;301-304.
11. Ishizuka H., Watnanbe M., Kubota T. Antitumor activity of murine monoclonal antibody NCC-ST-421 on human cancer cells by inducing apoptosis. Anticancer Res. 18:1998;2513-2518.
12. Baselga J., Mendelsohn J. Receptor blockade with monoclonal antibodies as anti-cancer therapy. Pharmacol Ther. 64:1994;127-154.
13. Fagerberg J., Frodin J. E., Ragnhammar P. Induction of an immune network cascade in cancer patients treated with monoclonal antibodies. Cancer Immunol Immunother. 38:1994;149-159.
14. Schmolling J., Reinsberg J., Wagner U., Krebs D. Antiidiotypic antibodies in ovarian cancer patients treated with the monoclonal antibody B72.3. Hybridoma. 14:1995;183-186.
15. Steplewski Z., Lubeck M., Koprowski H. Human macrophages armed with murine immunoglobulin G2a antibodies to tumors destroy human cancer cells. Science. 221:1983;865-868.
16. Hellstrom I., Beaumier P., Hellstrom K. E. Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas. Proc Natl Acad Sci USA. 83:1986;7060-7062.
17. Zeidler R., Reisbach G., Lindhofer H. Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J Immunol. 163:1999;1246-1252.
18. Ortaldo J. R., Woodhouse C., Morgan A. C. Analysis of effector cells in human antibody dependent cellular cytotoxicity with murine monoclonal antibodies. J Immunol. 138:1987;3566-3572.
19. Ballare C., Barrio M., Portela P., Mordoh J. Functional properties of FC-2.15, a monoclonal antibody that mediates human complement cytotoxicity against breast cancer cells. Cancer Immunol Immunother. 41:1995;15-22.
20. Carlsson J., Daniel-Szolgay E., Frykholm G. Homogeneous penetration but heterogeneous binding of antibodies to carcinoembryonic antigen in human colon carcinoma HT-29 spheroids. Cancer Immunol Immunother. 30:1989;269-276.
21. Gillaspy G., Miller R., Samols D., Goldthwait D. Antigenic and differentiative heterogeneity among human glioblastomas. Cancer Lett. 68:1993;215-224.
22. Wilder R. B., DeNardo G. L., DeNardo S. J. Radioimmunotherapy: recent results and future directions. J Clin Oncol. 14:1996;1383-1400.
23. Riva P., Franceschi G., Gentile R., Riva N., Casi M. Radioimmunodetection and radioimmunotherapy of breast cancer. Tumori. 83:1997;552-557.
24. Kreitman R. J. Immunotoxins in cancer therapy. Current Op Immunol. 11:1999;570-578.
25. Iglewski B. H., Liu P. V., Kabat D. Mechanism of action of Pseudomonas aeruginosa exotoxin adenosine diphosphate-ribosylation of mammalian elongation factor 2 in vitro and in vivo. Infect Immun. 15:1977;138-144.
26. Siegall C., Chace D., Mixani B. In vitro and in vivo characterization of BR96 sFv-PE40. J Immunol. 152:1994;2377-2384.
27. Zangemeister-Wittke U., Collinsoni A., Fisch I. Anti-tumor activity of a blocked ricin immunotoxin with specificity against the cluster-5A antigen associated with human small cell lung cancer. Int J Cancer. 54:1993;1028-1035.
28. Brusa P., Pietribiasi F., Bussolati G. Blocked and not blocked whole-ricin antibody immunotoxins: intraperitoneal therapy of human tumor xenografted in nude mice. Cancer Immunol Immunother. 29:1989;185-192.
29. Garnett M. C., Embleton M. J., Jacobs E., Baldwin R. W. Studies on the mechanism of action of an antibody-targeted drug-carrier conjugate. Anticancer Drug Des. 1:1985;3-12.
30. Bagshawe K. D., Sharma S. K., Burke P. J., Melton R. G., Knox R. J. Developments with targeted enzymes in cancer therapy. Current Op Immunol. 11:1999;579-583.
31. Khazaeli M. B., Conry R., LoBuglio A. Human immune response to monoclonal antibodies. J Immunol. 15:1994;42-52.
32. Sakahara H., Saga T., Onodera H. Anti-murine antibody response to mouse monoclonal antibodies in cancer patients. Jpn J Can Res. 88:1997;895-899.
33. Boulianne G., Hozumi N., Shulman M. Production of functional chimaeric mouse/human antibody. Nature. 312:1984;643-646.
34. Rodwell J. D. Engineering monoclonal antibodies. Nature. 342:1989;99-100.
35. Buist M. R., Kenemans P., van Kamp G., Haisma H. Minor human antibody response to a mouse and chimeric monoclonal antibody after a single I.V. infusion in ovarian carcinoma patients: a comparison of five assays. Cancer Immunol Immunother. 40:1995;24-30.
36. Van Zaanen H., Lokhorsti H., Aarden L., van Oers M. Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of an advanced multiple myeloma: a phase I dose-escalating study. Br J Haematol. 102:1998;783-790.
37. Goodman G., Hellstrom I., Yeltoni D. Phase I trial of chimeric (human-mouse) monoclonal antibody L6 in patients with non-small cell lung, colon and breast cancer. Cancer Immunol Immunother. 36:1993;267-273.
38. Jones P., Dear P., Foote J., Neuberger M., Winter G. Replacing the complementarity-determining region in a human antibody with those from a mouse. Nature. 321:1986;522-525.
39. Riechmann L., Clark M., Waldmann H., Winter G. Reshaping human antibodies for therapy. Nature. 332:1988;323-327.
40. Anasetti C., Martin P., Morishita Y. Human large granular lymphocytes express high affinity receptors for murine monoclonal antibodies of the IgG3 subclass. J Immuno. 138:1987;2979-2981.
41. Rodwell J. D. Engineering monoclonal antibodies. Nature. 342:1989;99-100.
42. H2 domain and directed against the disialoganglioside GD2. Proc Natl Acad Sci USA. 87:1990;5702-5705.
43. Jain R. K., Baxter L. T. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res. 48:1988;7022-7031.
44. Sutherland R., Buchegger F., Mach J. P. Penetration and binding of radiolabeled anti-carcinoembryonic antigen monoclonal antibodies and their antigen binding fragments in human colon multicellular tumor spheroids. Cancer Res. 47:1987;1627-1633.
45. Yui B., Carrasquillo J., Milenic D. Phase I trial of iodine 131-labeled COL-1 in patients with gastrointestinal malignancies: influence of serum carcinoembryonic antigen and tumor bulk on pharmacokinetics. J Clin Oncol. 14:1996;1798-1809.
46. Saleh M. N., Khazaeli M. B., Wheeler R. H. Phase I trial of the murine monoclonal anti-GD2 antibody 14G2a in metastatic melanoma. Cancer Res. 52:1992;35294-35300.
47. Schlom J. Monoclonal antibodies: They are more and less than you think. Broder S. Molecular and Cellular Research for Future Diagnosis and Therapy. 1990;95-97 Williams and Wilkins, Baltimore.
48. Tedder T. F., Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today. 15:1994;450-454.
49. Press O. W., Appelbaum F., Ledbetter J. A., Martin P. J., Thomas E. D. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood. 69:1987;584-591.
50. Maloney D. G., Grillo-Lopez A. J., Bodkin D. J. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol. 15:1997;3266-3274.
51. Maloney D. G., Grillo-Lopez A. J., White C. A. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 90:1997;2188-2195.
52. Grillo-Lopez A. J., White C. A., Varns C. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol. 26:1999;66-73.
53. McLaughlin P., Grillo-Lopez A. J., Link B. K. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 16:1998;2825-2833.
54. Berinstein N. L., Grillo-Lopez A. J., White C. A. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol. 9:1998;995-1001.
55. McLaughlin P., Hagemeister F. B., Grillo-Lopez A. J. Rituximab in indolent lymphoma: the single agent pivotal trial. Semin Oncol. 26:1999;79-87.
56. McLaughlin P., Hagemeister F. B., Grillo-Lopez A. J. Rituximab in indolent lymphoma: the single agent pivotal trial. Semin Oncol. 26:1999;79-87.
57. O'Brein S., Freireich E., Andreeff M. Phase I/II study of Rituxan in chronic lymphocytic leukemia (CLL). Blood. 92:1998.
58. Foran J. M., Rohatiner A. Z., Cunningham D. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma and small B-cell lymphocytic lymphoma. J Clin Oncol. 18:2000;317-324.
59. Byrd J. C., White C. A., Link B. Rituximab therapy in Waldenstrom's macroglobulinemia: preliminary evidence of clinical activity. Ann Oncol. 10:1999;1525-1527.
60. Czuczman M. S., Grillo-Lopez A. J., White C. A. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol. 17:1999;268-276.
61. Press O. W. Radiolabeled antibody therapy of B-cell lymphomas. Semin Oncol. 26:1999;58-65.
62. Rosen, S. T. Recent advances and future directions using monoclonal antibodies for B-cell malignancies. Proceedings of a conference. Kaupulehu, Hawaii, USA. January 1999. Semin Oncol, 1999, 26, 1, 122.
63. Rosen, S. T. Recent advances and future directions using monoclonal antibodies for B-cell malignancies. Proceedings of a conference. Kaupulehu, Hawaii, USA. January 1999. Semin Oncol, 1999, 26, 1, 122.
64. Slamon D. J., Clark G. M., Wong S. G. Human breast cancer: correlation of relapse and survival with amplification of the Her-2/neu oncogene. Science. 235:1987;177-181.
65. Saranath D., Panchal R. G., Nair R. Amplification and overexpression of epidermal growth factor receptor gene in human oropharyngeal cancer. Eur J Cancer. 28B:1992;139-143.
66. Rusch V., Baselga J., Cordon-Cardo C. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res. 53:1993;2379-2385.
67. Kawamoto K., Onodera H., Kan S., Kondo S., Imamura M. Possible paracrine mechanism of insulin-like growth factor-2 in the development of liver metastases from colorectal cancer. Cancer. 85:1999;18-25.
68. Ruck A., Paulie S. EGF, TGF alpha, AR and HG-EGF are autocrine growth factors for human bladder carcinoma cell lines. Anticancer Res. 18:1998;1447-1452.
69. Huang S. M., Bock J. M., Harari P. M. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 59:1999;1935-1940.
70. Baselga J., Mendelsohn J. The epidermal growth factor receptor as a target for therapy in breast carcinoma. Breast Cancer Res Treat. 29:1994;127-138.
71. Reissmann P. T., Koga H., Figlin R. A., Holmes E. C., Slamon D. J. Amplification and overexpression of the cyclin D1 and epidermal growth factor receptor genes in non-small-cell lung cancer. Lung Cancer Study Group. J Cancer Res Clin Oncol. 125:1999;61-70.
72. Di Marco E., Albanese E., Benso S. Expression of epidermal growth factor receptor and transforming growth factor alpha in human larynx carcinoma. Cancer Lett. 65:1992;189-199.
73. Baselga J., Mendelsohn J. Receptor blockade with monoclonal antibodies as anti-cancer therapy. Pharmacol Ther. 64:1994;127-154.
74. Aaronson S. A. Growth factors and cancer. Science. 254:1991;1146-1152.
75. Goldstein N. I., Prewett M., Zuklys K., Rockwell P., Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res. 1:1995;1311-1318.
76. Prewett M., Rockwell P., Rockwell R. F. The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. J Immunother Emphasis Tumor Immunol. 19:1996;419-427.
77. Gunnett K., Motzer R., Amato R. Phase II study of anti-epidermal growth factor receptor antibody C225 alone in patients with metastatic renal cell carcinoma. Proc ASCO. 1999;1309.
78. Baselga J., Mendelsohn J. Receptor blockade with monoclonal antibodies as anti-cancer therapy. Pharmacol Ther. 64:1994;127-154.
79. Mendelsohn J., Shin D. M., Donato N. A phase I study of the chimerized anti-epidermal growth factor receptor monoclonal antibody, C225, in combination with cisplatin in patients with recurrent head and neck squamous cell carcinoma. Proc. ASCO. 1999;1502.
80. Lei W., Mayotte J. E., Levitt M. L. Enhancement of chemosensitivity and programmed cell death by tyrosine kinase inhibitors correlates with EGFR expression in non-small cell lung cancer cells. Anticancer Res. 19:1999;221-228.
81. Huang S. M., Bock J. M., Harari P. M. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 59:1999;1935-1940.
82. Ezekiel M. P., Bonner J. A., Robert F. Phase I trial of chimerized anti-epidermal growth factor receptor antibody in combination with either once-daily or twice-daily irradiation for locally advanced head and neck malignancies. Proc. ASCO. 1999;1501.
83. Perrotte P., Matsumoto T., Inoue K. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res. 5:1999;257-265.
84. Modjtahedi H., Eccles S., Box G., Styles J., Dean C. Immunotherapy of human tumour xenografts overexpressing the EGF receptor with rat antibodies that block growth factor-receptor interaction. Br J Cancer. 67:1993;254-261.
85. Yang X. D., Jia X. C., Corvalan J. R. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res. 59:1999;1236-1243.
86. Baselga J., Mendelsohn J. Receptor blockade with monoclonal antibodies as anti-cancer therapy. Pharmacol Ther. 64:1994;127-154.
87. Press M. F., Cordon-Cardo C., Slamon D. J. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissue. Oncogene. 5:1990;953-962.
88. Slamon D. J., Clark G. M., Wong S. G., Levin W. J., Ullrich A., McGuire W. L. Human breast cancer: correlation of relapse and survival with amplification of the Her-2/neu oncogene. Science. 253:1987;177-181.
89. Cline M. J., Battifora H. Abnormalities of proto-oncogenes in non-small cell lung cancer. Correlations with tumor type and clinical characteristics. Cancer. 61:1987;2669-2674.
90. Berchuck A., Kamel A., Whitaker R. Overexpression of Her-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 50:1990;4087-4091.
91. Gu K., Mes-Masson A. M., Gauthier J., Saad F. Overexpression of her-2/neu in human prostate cancer and benign hyperplasia. Cancer Lett. 99:1996;185-189.
92. Pauletti G., Godolphin W., Press M. F., Slamon D. J. Detection and quantitation of Her-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene. 13:1996;63-72.
93. Slamon D. J., Clark G. M., Wong S. G. Human breast cancer: correlation of relapse and survival with amplification of the Her-2/neu oncogene. Science. 253:1987;177-181.
94. Chazin V. R., Kaleko M., Miller A. D., Slamon D. J. Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor. Oncogene. 7:1992;1859-1866.
95. Tiwari R. K., Borgen P. I., Wong G. Y. HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis. Anticancer Res. 12:1992;419-425.
96. Kallioniemi O. P., Holli K., Visakorpi T. Association of c-erbB-2 protein overexpression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer. 49:1991;650-655.
97. Tandon A. K., Clark G. M., Chamness G. C. HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol. 7:1989;1120-1128.
98. Paik S., Hazan R., Fisher E. R. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol. 8:1990;103-112.
99. Gusterson B. A., Gelber R. D., Goldhirsch A. Prognostic importance of c-erb-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol. 10:1992;1049-1056.
100. Paik S., Hazan R., Fisher E. R. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol. 8:1990;103-112.
101. Seshadri R., Firgaira F., Horsfall D. Clinical significance of Her-2/neu oncogene amplification in primary breast cancer. J Clin Oncol. 11:1993;1936-1942.
102. Paterson M. C., Dietrich K. D., Danyluk J. Correlation between c-erb-2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer Res. 51:1991;556-567.
103. Gusterson B. A., Gelber R. D., Goldhirsch A. Prognostic importance of c-erb-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol. 10:1992;1049-1056.
104. Allred D. C., Clark G. M., Tandon A. K. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol. 10:1992;599-605.
105. Menard S., Valagussa P., Pilotti S. Benefit of CMF treatment in lymph node-positive breast cancer overexpressing HER2. Proc. ASCO. 1999;257.
106. Pegram M. D., Finn R. S., Arzoo K. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian carcinomas. Oncogene. 15:1997;537-547.
107. Muss H. B., Thor A. D., Berry D. A. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. NEJM. 330:1994;1260-1266.
108. Vera R., Albanell J., Lirola J. L. HER2 overexpression as a predictor of survival in a trial comparing adjuvant FAC and CMF in breast cancer. Proc. ASCO. 1999;265.
109. Wright C., Nicholson S., Angus B. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer. 65:1992;118-121.
110. Carlomango C., Perrone F., Gallo C. c-erbB-2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol. 14:1996;2702-2708.
111. Elledge R. M., Green S., Ciocca D. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer, a Southwest Oncology Group Study. Clin Cancer Res. 4:1998;7-12.
112. Muss H., Berry D., Thor A. Lack of interaction of tamoxifen (T) use and ErbB-2/HER-2/Neu (H) expression in CALGB 8541: a randomized adjuvant trial of three different doses of cyclophosphamide, doxorubicin and fluorouracil (CAF) in node-positive primary breast cancer. Proc. ASCO. 1999;256.
113. Hsieh C. C., Chow K. C., Fahn H. J. Prognostic significance of HER-2/neu overexpression in stage I adenocarcinoma of lung. Ann Thorac Surg. 66:1998;1159-1163.
114. Harpole D. H., Marks J. R., Richards W. G. Localized adenocarcinoma of the lung: oncogene expression of erbB-2 and p53 in 150 patients. Clin Cancer Res. 1:1995;659-664.
115. Xia W., Lau Y. K., Zhang H. Z. Strong correlation between c-erb-2 overexpression and overall survival of patients with oral squamous cell carcinoma. Clin Cancer Res. 3:1997;3-9.
116. Kim Y. T., Kim J. W., Lee J. W. c-erbB-2 oncoprotein assay in ovarian carcinoma and its clinical correlation with prognostic factors. Cancer Lett. 132:1998;91-97.
117. Morote J., de Torres I., Caceres C. Prognostic value of immunohistochemical expression of the c-erbB-2 oncoprotein in metastatic prostate cancer. Int J Cancer. 84:1999;421-425.
118. Drebin J. A., Link V. C., Winberg R. A., Greene M. I. Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen. Proc Natl Acad Sci USA. 83:1986;9129-9133.
119. Hudziak R. M., Lewis G. D., Winget M. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol. 9:1989;1165-1172.
120. Sarup J. C., Johnson R. M., King K. L. Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth. Growth Regul. 1:1991;72-82.
121. Shepard H. M., Lewis G. D., Sarup J. C. Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic. J Clin Immunol. 11:1991;117-127.
122. Carter P., Presta L., Gorman C. M. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA. 89:1992;4285-4289.
123. Baselga J., Tripathy T., Mendelsohn J. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu overexpressing metastatic breast cancer. J Clin Oncol. 14:1996;737-744.
124. Cobleigh M. A., Vogel C. L., Tripathy D. Efficacy and safety of Herceptin (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who had relapsed following chemotherapy for metastatic breast cancer. Proc. ASCO. 1998;376.
125. Pegram M. D., Lipton A., Hayes D. F. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol. 16:1998;2659-2671.
126. Baselga J., Norton L., Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 58:1998;2825-2831.
127. Slamon D., Leyland-Jones B., Shak S. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: a randomized, multinational controlled phase III trial. Proc. ASCO. 1998;377.
128. Norton L., Slamon D., Leyland-Jones B. Overall survival (OS) advantage to simultaneous chemotherapy (CRx) plus the humanized anti-HER2 monoclonal antibody Herceptin (H) in HER2 overexpressing (HER2+) metastatic breast cancer (MBC). Proc. ASCO. 1999;483.
129. Slamon D., Leyland-Jones B., Shak S. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: a randomized, multinational controlled phase III trial. Proc. ASCO. 1998;377.
130. Pietras R. J., Poen J. C., Gallardo D. Monoclonal antibody to HER-2/neu receptor modulates repair of radiation induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this tumor. Cancer Res. 59:1999;1347-1355.
131. Kern J. A., Torney L., Weiner D. Inhibition of human lung cancer cell line growth by an anti-p185HER2 antibody. Am J Respir Cell Mol Biol. 9:1993;448-454.
132. Hellstrom I., Garrigues H. J., Garrigues U., Hellstrom K. E. Highly tumor-reactive, internalizing mouse monoclonal antibodies to Le(y)-related cell surface antigens. Cancer Res. 50:1990;2183-2190.
133. Schreiber G. J., Hellstrom K. E., Hellstrom I. An unmodified anticarcinoma antibody BR96, localizes to and inhibits the outgrowth of human tumors in nude mice. Cancer Res. 52:1992;3262-3266.
134. Trail P. A., Willner D., Lasch S. J. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science. 261:1993;212-215.
135. Tolcher A. W., Sugarman S., Gelmon K. A. Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J Clin Oncol. 17:1999;478-484.
136. Siegall C. B., Chace D., Mixan B. In vitro and in vivo characteristics of BR96 sFv-PE40. J Immunol. 152:1994;2377-2384.
137. Hellstrom I., Beaumier P. L., Hellstrom K. E. Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas. Proc Natl Acad Sci USA. 83:1986;7059-7063.
138. Goodman G. E., Hellstrom I., Brodzinsky L. Phase I trial of murine monoclonal antibody L6 in breast, colon, ovarian and lung cancer. J Clin Oncol. 8:1990;1083-1092.
139. Goodman G. E., Hellstrom I., Yelton D. E. Phase I trial of chimeric (human-mouse) monoclonal antibody L6 in patients with non-small-cell lung, colon and breast cancer. Cancer Immunol Immunother. 36:1993;267-273.
140. Denardo S. J., O'Grady L. F., Richman C. M. Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody. Anticancer Res. 17:1997;1745-1751.
141. Mordoh J., Leis S., Bravo A. I. Description of a new monoclonal antibody FC-2.15, reactive with human breast cancer and other neoplasms. Int J Biol Markers. 9:1994;125-134.
142. Braun S., Janni W., Hepp F. Monitoring of reduction of 17-1A expressing breast cancer micrometastases during antibody therapy with Edrecolomab - a pilot study. Proc. ASCO. 1999;1728.
143. Tripathi P. K., Qin H., Chatterjee S. K. Construction and characterization of a chimeric fusion protein consisting of an anti-idiotype antibody mimicking a breast cancer-associated antigen and the cytokine GM-CSF. Hybridoma. 18:1999;193-202.
144. Kramer E. L., Liebes L., Wasserheit C., Ceriani R. L. Initial clinical evaluation of radiolabeled MX-DTPA humanized BrE-3 antibody in patients with advanced breast cancer. Clin Cancer Res. 4:1998;1679-1688.
145. Foon K. A., Yannelli J., Bhattacharya-Chatterjee M. Colorectal cancer as a model for immunotherapy. Clin Cancer Res. 5:1999;225-236.
146. Litvinov S. V., Velders M. P., Warnaar S. O. Ep-CAM: a human epithelial antigen is a homophillic cell-cell adhesion molecule. J Cell Biol. 125:1994;437-446.
147. Herlyn D., Steplewski Z., Herlyn M. F., Koprowski H. Inhibition of growth of colorectal carcinoma in nude mice by monoclonal antibody. Cancer Res. 40:1980;717-721.
148. Lobuglio A. F., Saleh M., Peterson L. Phase I clinical trial of CO17-1A monoclonal antibody. Hybridoma. 5(Suppl. 1):1986;S117-123.
149. Mellstedt H., Frodin J. E., Ragnhammar P. The clinical use of monoclonal antibodies, Mab 17-1A, in the treatment of patients with metastatic colorectal carcinoma. Med Oncol Tumor Pharmacother. 6:1989;99-107.
150. Riethmuller G., Holz E., Schlimok G. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol. 16:1998;1788-1794.
151. Riethmuller G., Schneider-Gadicke E., Schlimok G. Randomized trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group. Lancet. 343:1994;1117-1183.
152. Fields A. L., Nagy A., Schwartzberg L. Edrecolomab (Panorex™, 17-1a Antibody) alone or in combination with 5-FU based chemotherapy in adjuvant treatment of stage III colon cancer: A safety review. Proc. ASCO. 1999;1676.
153. Pullyblank A. M., Monson R. T. Monoclonal antibody therapy of colorectal cancer. Br J Surg. 84:1997;1511-1517.
154. Guadagni F., Roselli M., Cosimelli M. TAG-72 expression and its role in the biological evaluation of human colorectal cancer. Anticancer Res. 16:1996;2141-2148.
155. Mulligan T., Carrasquillo J. A., Curt G. Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma. Clin Cancer Res. 1:1995;1447-1454.
156. Murray J. L., Macey D. J., Podoloff D. A. Phase II radioimmunotherapy trial with 131I-CC49 in colorectal cancer. Cancer. 73:1994;1057-1066.
157. Kashmiri S. V., Shu L., Hand P. H. Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49. Hybridoma. 14:1995;461-473.
158. Yi E. S., Harclerode D., Gondo M. High c-erB-3 protein expression is associated with shorter survival in advanced non-small cell lung carcinomas. Mod Pathol. 10:1997;142-148.
159. Zia F., Jacobs S., Kull F. Monoclonal antibody alpha IR-3 inhibits non-small cell lung cancer growth in vitro and in vivo. J Cell Biochem Suppl. 24:1996;269-275.
160. Martin A., Pellen P., Guitton C. Characterization of the antigen identified by Po66. A monoclonal antibody raised against a lung squamous cell carcinoma. Cancer Immunol Immunother. 29:1989;118-124.
161. Dazord L., Bourel D., Martin A. A monoclonal antibody (Po66) directed against human lung squamous cell carcinoma immunolocalization of tumour xenografts in nude mice. Cancer Immunol Immunother. 24:1989;263-268.
162. Desrues B., Brichory F., Lena H. Treatment of human lung carcinoma xenografts with a combination of 131I-labeled monoclonal antibody Po66 and doxorubicin. Cancer Immunol Immunother. 43:1996;269-274.
163. Lantuejoul S., Moro D., Michalides R. J. Neural cell adhesion molecules (NCAM) and NCAM-PSA expression in neuroendocrine lung tumors. Am J Surg Path. 22:1998;1267-1276.
164. Hage R., Elbers H. R., Brutel de la Riviere A., van den Bosch J. M. Neural cell adhesion molecule expression: prognosis in 889 patients with resected non-small cell lung cancer. Chest. 114:1998;1316-1320.
165. Kwa H. B., Verheijen M. G., Van Krieken J. H. Prognostic factors in resected non-small cell lung cancer: an immunohistochemical study of 39 cases. Lung Cancer. 16:1996;35-45.
166. Moolenaar C. E., Muller E. J., Schol D. J. Expression of neural cell adhesion molecule-related sialoglycoprotein in small cell lung cancer and in neuroblastoma cell lines H69 and CHP-212. Cancer Res. 50:1990;1102-1106.
167. Gilks W. R., Stahel R. A., Walker N., Schenker T. Statistical analysis of data from the third international IALSC workshop on lung tumor and differentiation antigens. Int J Cancer. (Suppl. 8):1994;2-5.
168. Lynch T. J. Immunotoxin of small-cell lung cancer. N901-blocked ricin for relapsed small-cell lung cancer. Chest. 103:1993;436s-439s.
169. Lynch T. J., Lambert J. M., Coral F. Immunotoxin therapy of small cell lung cancer: A phase I study of N901-blocked ricin. J Clin Oncol. 15:1997;723-734.
170. Johnson B. E., Kelley M. J. Autocrine growth factors and neuroendocrine markers in the development of small-cell lung cancer. Oncology. 12(Suppl. 2):1998;11-14.
171. Kelley M. J., Linnoila R. I., Avis I. L. Antitumor activity of a monoclonal antibody directed against gastrin-releasing peptide in patients with small cell lung cancer. Chest. 112:1997;256-261.
172. Schlaeppi J. M., Siemeister G., Wood J. Characterization of a new potent, in vivo neutralizing monoclonal antibody to human vascular endothelial growth factor. J Cancer Res Clin Oncol. 125:1999;336-342.